Immunogenicity Summit

Immunogenicity Risk Assessment and Mitigation 

Investigators are continuing to study the causes of immunogenicity such as particular amino acid sequences, peptides and epitopes, and the propensity to aggregate, and are developing models and tools for risk prediction. Meanwhile innovative approaches are being devised to reduce immunogenicity and/or induce tolerance. This track will provide case studies on identification of risk factors and on how investigators translate their findings into a risk assessment strategy to enable them to decide on whether to take a product into clinical studies in patients and beyond, and on means of reducing potential immunogenicity.

Topics to be covered include:

  • Identification of risk factors
  • Predictive models and tools for risk prediction
  • Analysis of the immunogenicity data in a meaningful way
  • Putting together predictive findings to determine risk in the clinic
  • Translating guidance and white papers on risk into a strategy
  • Case studies on determination of risk for a range of biotherapeutics
  • Characterization of aggregates and classification for propensity to induce immunogenicity
  • Case studies of the impact of the process on aggregation, PKPD and immunogenicity
  • Immune tolerance approaches and methods for reducing immunogenicity

If you are interested in presenting, please click here to submit a speaking proposal for review. Please note that due to limited speaking slots, preference is given to abstracts from those within pharmaceutical and biotech companies, regulators and those from academic centers.  Additionally, as per CHI policy, a select number of vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.

Deadline for submission is May 3, 2013.


We truly welcome your comments, suggestions and speaker referrals as we shape the 2013 program.

For questions or suggestions about the meeting, please contact:
Nicole Lyscom B.Sc. M.Sc. Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: +44 7791 866489
Email: nlyscom@healthtech.com     

For exhibit and sponsorship opportunities, contact:
Tim McLucas
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-1342
Email: tmclucas@healthtech.com 

For marketing and media partnerships, please contact:
James Prudhomme
Senior Marketing Manager
Cambridge Healthtech Institute
Phone: 781-972-5486
Email: jprudhomme@healthtech.com